M
017180
vs
K
KOSPI 200
Over the past 12 months, Myungmoon Pharm Co Ltd has underperformed KOSPI 200, delivering a return of -6% compared to the KOSPI 200's +98% growth.
Stocks Performance
017180 vs KOSPI 200
Performance Gap
017180 vs KOSPI 200
Performance By Year
017180 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Myungmoon Pharm Co Ltd
Glance View
MYUNGMOON Pharm Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-07-10. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The firm is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.